The Level of Circulating Microparticles in Patients with Coronary Heart Disease: a Systematic Review and Meta-Analysis

Wang, Baofu; Li, Tong; Han, Xiao; Yang, Li; Cheng, Wenkun; Wang, Lei; Lu, Ziwen; Yang, Jingjing; Zhao, Mingjing

doi:10.1007/s12265-019-09945-7

Cited by 18 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were obtained in a prospective, case-controlled study including 84 patients with CAD and 42 control subjects [165]. Elevated numbers of CD31-positive, CD42b-negative MPs were found to discriminate patients with ACS from those with stable angina [166]. Interestingly, platelet-EV numbers did not differ in those studies, although a correlation between CD31-positive endothelial EVs and platelet-EVs was observed [27,165], potentially also due to the overlap of antigen expression on the surface of both cell types, as mentioned earlier.…”

Section: Evs and Thrombosis In The Arterial System: Clinical Evidencesupporting

confidence: 81%

“…A systematic review and meta-analysis of 11 observational studies performed before 2015 revealed significant differences in plasma platelet-EV concentrations between patients with ACS and healthy controls, whereas their numbers did not differ compared to patients with stable angina [168]. More recently, a meta-analysis of case-control studies revealed higher levels of EVs, including CD31-positive, CD42-negative and CD144-positive endothelial EVs, in patients with coronary heart disease (CHD) compared to controls, and their numbers were also higher in patients with MI vs. unstable angina vs. stable angina [166].…”

Section: Evs and Thrombosis In The Arterial System: Clinical Evidencementioning

confidence: 99%

See 1 more Smart Citation

Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence

Zifkos

Dubois

Schäfer

2021

IJMS

View full text Add to dashboard Cite

Extracellular vesicles (EVs) compose a heterogenous group of membrane-derived particles, including exosomes, microvesicles and apoptotic bodies, which are released into the extracellular environment in response to proinflammatory or proapoptotic stimuli. From earlier studies suggesting that EV shedding constitutes a cellular clearance mechanism, it has become evident that EV formation, secretion and uptake represent important mechanisms of intercellular communication and exchange of a wide variety of molecules, with relevance in both physiological and pathological situations. The putative role of EVs in hemostasis and thrombosis is supported by clinical and experimental studies unraveling how these cell-derived structures affect clot formation (and resolution). From those studies, it has become clear that the prothrombotic effects of EVs are not restricted to the exposure of tissue factor (TF) and phosphatidylserines (PS), but also involve multiplication of procoagulant surfaces, cross-linking of different cellular players at the site of injury and transfer of activation signals to other cell types. Here, we summarize the existing and novel clinical and experimental evidence on the role and function of EVs during arterial and venous thrombus formation and how they may be used as biomarkers as well as therapeutic vectors.

show abstract

Section: Evs and Thrombosis In The Arterial System: Clinical Evidencesupporting

confidence: 81%

Section: Evs and Thrombosis In The Arterial System: Clinical Evidencementioning

confidence: 99%

Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence

Zifkos

Dubois

Schäfer

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Furthermore, there is evidence indicating that galectin-3 may be a promising biomarker for evaluation of severity and prognosis of AMI (146). Recently, it was demonstrated that the levels of microparticles (MPs), especially CD31 + CD42 − EMPs and CD144 + EMPs, have the order of normal subjects < stable angina < unstable angina < MI, indicating that MPs have the potential capacity to distinguish stable angina, unstable angina, and MI (147).…”

Section: The Other Functions Of MI Biomarkersmentioning

confidence: 99%

Diagnostic and Prognostic Biomarkers for Myocardial Infarction

Pan

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The incidence of myocardial infarction (MI) increases every year worldwide. Better diagnostic and prognostic biomarkers for clinical applications are the consistent pursuit of MI research. In addition to electrocardiogram, echocardiography, coronary angiography, etc., circulating biomarkers are essential for the diagnosis, prognosis, and treatment effect monitoring of MI patients. In this review, we assessed both strength and weakness of MI circulating biomarkers including: (1) originated from damaged myocardial tissues including current golden standard cardiac troponin, (2) released from non-myocardial tissues due to MI-induced systems reactions, and (3) preexisted in blood circulation before the occurrence of MI event. We also summarized newly reported MI biomarkers. We proposed that the biomarkers preexisting in blood circulation before MI incidents should be emphasized in research and development for MI prevention in near future.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Microparticles or microvesicles (MPs/MVs) are small membrane vesicles shed from cells with the number and cargo varying depending on the stimuli to the parent cell [1][2][3]. Red blood cell (RBC)-derived MVs (RMVs) are formed constitutively [4,5] and in greater numbers following oxidative damage [6], hemolysis, or even ischemic injury [3,7,8]. Red blood cell-derived MVs carry biologically active macromolecules [9,10], such as exposed phosphatidylserine (PS) and phosphatidylethanolamine [11], which are critical in coagulation [12].…”

Section: Introductionmentioning

confidence: 99%

Centrifugation Removes a Population of Large Vesicles, or “Macroparticles,” Intermediate in Size to RBCs and Microvesicles

Larson

Hogg

Hillery

2021

IJMS

View full text Add to dashboard Cite

Microparticles or microvesicles (MPs/MVs) are sub-cellular vesicles with a growing number of known biological functions. Microvesicles from a variety of parent cells within the vascular system increase in numerous pathological states. Red blood cell-derived MVs (RMVs) are relatively less studied than other types of circulating MVs despite red blood cells (RBCs) being the most abundant intravascular cell. This may be in part due the echoes of past misconceptions that RBCs were merely floating anucleate bags of hemoglobin rather than dynamic and responsive cells. The initial aim of this study was to maximize the concentration of RMVs derived from various blood or blood products by focusing on the optimal isolation conditions without creating more MVs from artificial manipulation. We found that allowing RBCs to sediment overnight resulted in a continuum in size of RBC membrane-containing fragments or vesicles extending beyond the 1 µm size limit suggested by many as the maximal size of an MV. Additionally, dilution and centrifugation factors were studied that altered the resultant MV population concentration. The heterogeneous size of RMVs was confirmed in mice models of hemolytic anemia. This methodological finding establishes a new paradigm in that it blurs the line between RBC, fragment, and RMV as well as suggests that the concentration of circulating RMVs may be widely underestimated given that centrifugation removes the majority of such RBC-derived membrane-containing particles.

show abstract

The Level of Circulating Microparticles in Patients with Coronary Heart Disease: a Systematic Review and Meta-Analysis

Cited by 18 publications

References 41 publications

Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence

Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence

Diagnostic and Prognostic Biomarkers for Myocardial Infarction

Centrifugation Removes a Population of Large Vesicles, or “Macroparticles,” Intermediate in Size to RBCs and Microvesicles

Contact Info

Product

Resources

About